TNF-alpha inhibitor - C4X Discovery
Alternative Names: TNFα inhibitor - C4X DiscoveryLatest Information Update: 25 Sep 2025
At a glance
- Originator C4X Discovery
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 22 Sep 2025 TNF-alpha inhibitor - C4X Discovery is available for licensing as of 22 Sep 2025. https://c4xdiscovery.com/portfolio/
- 22 Jul 2024 Early research in Inflammatory bowel diseases in United Arab Emirates (PO), prior to July 2024
- 22 Jul 2024 Early research in Rheumatoid arthritis in United Kingdom (PO), prior to July 2024